Allergan, Ironwood deal

Allergan granted Ironwood rights to co-promote Viberzi eluxadoline in the U.S. Ironwood will promote Viberzi to about 25,000 healthcare practitioners to whom the company promotes Linzess linaclotide for constipation and irritable bowel syndrome (IBS) under a separate co-development and co-commercialization deal with Allergan. Allergan will compensate Ironwood based on the volume of calls delivered by Ironwood’s sales force and on undisclosed performance metrics and will be responsible for all other commercialization costs. Ironwood also will be eligible for undisclosed sales milestones. ...